By Dr .Muhammad Mosleh Uddin â€ĸ 02 Aug, 2026

Can we predict diabetic CKD progression before albuminuria or eGFR starts to deteriorate?

🔴 Can we predict DKD progression before albuminuria or eGFR starts to deteriorate? āφāĻŽāϰāĻž āĻāĻ–āύ⧋ Diabetic Kidney Disease (DKD) āύāĻŋāĻ°ā§āĻŖā§Ÿā§‡āϰ āϜāĻ¨ā§āϝ āĻŽā§‚āϞāϤ albuminuria āĻāĻŦāĻ‚ eGFR-āĻāϰ āωāĻĒāϰ āύāĻŋāĻ°ā§āĻ­āϰ āĻ•āϰāĻŋāĨ¤ āĻ•āĻŋāĻ¨ā§āϤ⧁ āϏāĻŽāĻ¸ā§āϝāĻž āĻšāϞ⧋, āĻāχ marker āϗ⧁āϞ⧋ āĻ…āύ⧇āĻ• āϏāĻŽā§Ÿ kidney damage āĻļ⧁āϰ⧁ āĻšāĻ“ā§ŸāĻžāϰ āĻ…āύ⧇āĻ• āĻĒāϰ⧇ āĻĻ⧇āĻ–āĻž āϝāĻžā§ŸāĨ¤ āϤāĻžāχ āĻŦāĻ°ā§āϤāĻŽāĻžāύ nephrology research-āĻāϰ āϏāĻŦāĻšā§‡ā§Ÿā§‡ concern āĻāϰ āĻŦāĻŋāώ⧟ āĻšāϞ⧋, 🔴 Can we predict DKD progression before albuminuria or eGFR starts to deteriorate? āĻāχ āĻĒā§āϰāĻļā§āύ⧇āϰ āωāĻ¤ā§āϤāϰ āϖ⧁āρāϜāϤ⧇āχ āĻŦāĻŋāĻļā§āĻŦāĻœā§ā§œā§‡ āϚāϞāϛ⧇ intensive research on novel biomarkers. āĻāĻŦāĻ‚ āφāϞāĻšāĻžāĻŽāĻĻ⧁āϞāĻŋāĻ˛ā§āϞāĻžāĻš āφāĻŽāϰāĻž āĻĒā§‡ā§Ÿā§‡āĻ“ āϗ⧇āϞāĻžāĻŽ āĻ•āĻŋāϛ⧁ promising early biomarkers of diabetic CKD. āĻāĻ•āϟ⧁ briefly āĻŦāϞāĻŋ āφāĻĒāύāĻžāĻĻ⧇āϰ āχāύāĻļāĻž āφāĻ˛ā§āϞāĻžāĻšāĨ¤ 🔴 Urinary NGAL (Neutrophil Gelatinase-Associated Lipocalin) 📌 Detects early tubular injury 📌 May rise even before albuminuria 🔴 KIM-1 (Kidney Injury Molecule-1) 📌Marker of proximal tubular damage 📌Predicts faster kidney function decline 🔴 Cystatin C 📌More sensitive than serum creatinine 📌Better reflects early decline in GFR 🔴 Urinary L-FABP 📌Indicates renal hypoxia and oxidative stress 📌 Useful in detecting early DKD 🔴 TNFR-1 & TNFR-2 📌Among the strongest predictors of DKD progression 📌Associated with future end-stage kidney disease 🔴 Soluble Uromodulin 📌Reflects tubular health 📌Lower levels may indicate higher risk of progression 🔴 Urinary MCP-1 📌Marker of renal inflammation 📌Emerging predictor of DKD progression Kidney Extracellular Vesicle Biomarkers 📌A promising frontier in precision nephrology 📌Still largely confined to research settings āϝāĻĻāĻŋ āĻ­āĻŦāĻŋāĻˇā§āϝāϤ⧇ āĻāχ biomarkers-āϗ⧁āϞ⧋ routine clinical laboratory āϤ⧇ āĻ…āĻ‚āĻļ āĻšāϝāĻŧ⧇ āϝāĻžāϝāĻŧ, āϤāĻžāĻšāϞ⧇ āφāĻŽāϰāĻž high-risk patients āĻĻ⧇āϰ āĻ…āύ⧇āĻ• āφāϗ⧇āχ āĻļāύāĻžāĻ•ā§āϤ āĻ•āϰāϤ⧇ āĻĒāĻžāϰāĻŦā§‹ āχāύāĻļāĻž āφāĻ˛ā§āϞāĻžāĻšāĨ¤ āĻāĻŦāĻ‚ Chronic Kidney Disease (CKD) progression prevent āĻ•āϰāϤ⧇ āĻĒāĻžāϰāĻŦā§‹ āϖ⧁āĻŦ initial stage āĻĨ⧇āϕ⧇āχ āχāύāĻļāĻž āφāĻ˛ā§āϞāĻžāĻšāĨ¤ āĻāχ info āϗ⧁āϞ⧋ āϝ⧇āχ research paper āĻāϰ āωāĻĒāϰ based āĻ•āϰ⧇ āϞāĻŋāĻ–āĻž āϏ⧇āϗ⧁āϞ⧋āϰ link āύāĻŋāĻšā§‡ āĻĻāĻŋāϞāĻžāĻŽ āφāϞāĻšāĻžāĻŽāĻĻ⧁āϞāĻŋāĻ˛ā§āϞāĻžāĻšāĨ¤ Dr. Muhammad Mosleh Uddin MBBS (CMC). FCPS P1 (Cardiology)